Dare Bioscience (DARE) PT Lowered to $5 at Brookline Capital Markets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts DARE Hot Sheet
Price: $0.66 +1.54%
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 1
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 1
Join SI Premium – FREE
Brookline Capital Markets analyst Kemp Dolliver lowered the price target on Dare Bioscience (NASDAQ: DARE) to $5.00 (from $7.00) while maintaining a Buy rating.
You May Also Be Interested In
- UBS Downgrades PagSeguro (PAGS) to Neutral
- LeMaitre Vascular (LMAT) PT Lowered to $110 at Citizens on Slight EPS, EBITDA Misses
- HCI Group (HCI) PT Raised to $280 at Citizens on 'Better-Than-Expected 3Q26 Results'
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
